

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

Centres

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland; Spain* are open for inclusion.

Canada: ethics approval.


List of compounds under investigation

panna

Etravirine, Intelence, ETV
 Emtricitabine, Emtriva or FTC
 Tenofovir, Viread, TDF
 Atazanavir, Reyataz, ATV
 Fosamprenavir, Telzir, FPV
 Darunavir, Prezista, DRV
 Tipranavir, Aptivus, TPV
 Indinavir, Crixivan, IDV
 Raltegravir, Isentress, RAL
 Enfuvirtide, Fuzeon, T-20
 Maraviroc, Celsentri, MVC
 Efavirenz, Stocrin, EFV*
 *UK/Ireland only

Inclusions

66 subjects signed informed consent.



Emtricitabine / tenofovir arms closed now!

Just a reminder: patients on tenofovir / emtricitabine as the only compounds of the PANNA list cannot be included anymore. Atazanavir and darunavir are still open. Until we have 16 evaluable patients.

CROI poster

The first results of atazanavir, darunavir and ritonavir will be presented as a poster at the CROI 2012 in Seattle.

If you would like to receive the abstract you can contact Angela.

Sample shipments

Shipments via World Courier have been done for most sites now.

Thank you all!

CRFs

Angela will need data collected in the CRFs to prepare the CROI poster. She will contact you to send copies of the CRFs (by normal mail).

Amendment

In January 2012 an amendment will be issued to add rilpivirine to the list of ARVs under study.

Plans

We plan to submit an abstract to the HIV-PK workshop (tenofovir data). Abstract(s) will be sent to you for comments prior to submission. The first publications are expected in 2012.

Have a nice holiday season!



Angela and David

Angela Colbers
 Project manager
 E-mail: A.Colbers@akf.umcn.nl
 Radboud University Nijmegen Medical Centre, Internal postal code 864,
 Department of Pharmacy,
 P.O. Box 9101, 6500 HB Nijmegen
 Phone: + 31 (0)24 - 361 64 05
 Fax: + 31 (0)24- 366 87 55